Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

Eli Lilly & Co. (LLY) Earnings Forecast

Drugmaker Eli Lilly and Company (LLY) is scheduled to release its third-quarter results soon. While its revenue is expected to rise sharply over the prior-year quarter, its earnings are expected to decline. So, how should investors position themselves before the results are out? Read on to learn more….

StockNews.com

These 27 eye products could lead to infections and vision loss, FDA warns

If you find one of the products in your home you need to dispose of it immediately, the FDA says

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmacists prescribe another round of US protests to highlight working conditions

Drugstore employees around the country have started calling in sick to highlight a lack of support from their employers

The Independent UK

White House urges all US schools to stock overdose reversal drug naloxone

Letter from education department presses for schools to train students and faculty in how to administer medication

The Guardian - US

New Unilever boss is still getting it wrong on Russia

The Dove and Magnum maker says it wants to make a ‘positive impact’ but pays taxes to a state waging an illegal war in Ukraine

The Guardian - UK

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Life-saving overdose reversal drug expanded across Scotland

Community pharmacies across Scotland are being provided with a drug which can reverse overdoses.

The National (Scotland)

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

The Independent UK

US government says it plans to go after legal goods tied to illegal fentanyl trade in new strategy

The U.S. Customs and Border Protection has announced a new government-wide strategy that will target not only fentanyl but precursor materials used to make the synthetic opioid

The Independent UK

3 Pharma Stocks With Market Impact to Consider Buying

The pharmaceutical sector is expected to thrive due to the rising demand for advanced medicines to treat lifestyle diseases and its increasing ability to meet quality treatment needs thanks to technological advancements. Therefore, it could be wise to add fundamentally strong pharma stocks Amneal Pharmaceuticals (AMRX), Dr. Reddy’s Laboratories (RDY),…

StockNews.com

3 Pharma Stocks on the Rise - Buy Now

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. Thus, it would be prudent to buy pharma stocks, Sanofi (SNY), Johnson & Johnson (JNJ) and AstraZeneca PLC (AZN). Read on.

StockNews.com

Amgen cuts Horizon Therapeutics jobs at Deerfield office after acquisition

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

Chicago Sun-Times

3 Healthcare Stocks With Strong Stability

The healthcare industry is well-positioned for expansion due to rising healthcare expenditures and growing demand for quality treatment. Given the industry’s solid long-term prospects, investors might consider buying quality stocks Cigna (CI), UnitedHealth Group (UNH) and Elevance Health (ELV). Read on….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

The hospital ran out of her child's cancer drug. Now she's fighting to end shortages

Laura Bray couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.

WEKU

Law enforcement eyes opioid settlement cash for squad cars and body scanners

Some state and local governments have started tapping in to opioid settlement funds for law enforcement expenses. Many argue it should go toward treating addiction instead.

StockNews.com

3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks Equillium (EQ), Protalix BioTherapeutics (PLX), and Incyte Corporation (INCY) could make ideal additions to your portfolio at present. Read more….

Newsroom.co.nz

Medsafe overrides its Medicines Classification Committee on cannabis

The committee advised against over-the-counter CBD sales late last year

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Promising Pharma Stocks to Keep on Your Radar

The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma (ALPMY), Sanofi (SNY), and GSK (GSK) to one’s watchlist could be wise. Keep reading.

StockNews.com

3 Biotech Stocks for Long-Term Value

With medical innovations and a rising geriatric population, biotech stocks have garnered significant attention. Thus, sound biotech stocks like Genfit (GNFT), Entrada Therapeutics (TRDA), and MacroGenics (MGNX) could prove to be valuable portfolio additions in the long term. Read on….

StockNews.com

Abbott Laboratories (ABT) Earnings Insights: Will the Medical Stock Build Investor Confidence?

Considering Abbott Laboratories' (ABT) recent strategic collaborations and acquisitions to boost the company’s long-term growth, could the stock be a compelling buy as we approach its fiscal third-quarter earnings release? Let's find out.

The Independent UK

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products

Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

The Independent UK

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

1 … 38 39 40 41

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.